Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90009 combinations in AML
NCT04336982Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2020
- Primary completion
- Oct 2023
- Modality
- Molecular Glues
- Countries
- 5
01
Overview
Phase 1, open-label trial of eragidomide in acute myeloid leukemia (AML) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicity up to 28 days and Adverse Events. Started Aug 2020; status: terminated.
02
Drugs
eragidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04336982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336982.